舍曲林或认知行为疗法治疗癫痫伴抑郁的随机试验
该随机试验纳入140例癫痫合并重性抑郁障碍的成人门诊患者,比较舍曲林与每周认知行为疗法(CBT)共16周的疗效。意向性分析显示两组缓解率均超过历史安慰剂对照的上限,舍曲林与CBT缓解率相近,CBT组与舍曲林组生活质量均显著改善,两组在癫痫发作及自杀风险方面无显著差异。
要点
- 舍曲林与CBT对癫痫伴抑郁均有较好缓解率,且均优于历史安慰剂对照。
- 舍曲林未增加全面强直-阵挛发作或自杀风险。
- 抑郁持续与自杀风险相关,改善抑郁可提升生活质量。
核心结论
- 舍曲林或CBT治疗后略超过半数受试者抑郁缓解,两者疗效相当,且均不增加癫痫发作或自杀风险。
研究设计与样本
- 随机对照试验,纳入140例癫痫合并当前重性抑郁障碍的成人门诊患者,随机分配至舍曲林组或每周CBT组,疗程16周。
主要发现
- 舍曲林组72例中38例(52.8%;95%CI=±12)缓解,CBT组68例中41例(60.3%;95%CI=±11.6)缓解。
- 两组缓解时间差异为2.8天(95%CI=±0.43;p=0.79)。
- CBT组QOLIE-89评分平均改善25.7%(p<0.001),舍曲林组改善28.3%(p<0.001)。
- 两组全面强直-阵挛发作发生率差异为0.3%(95%CI=±8.6;p=0.95)。
- 最终评估时自杀风险与持续性抑郁相关(p<0.0001),与癫痫发作或舍曲林无关。
关键数值与推荐
- 舍曲林组缓解率下限高于历史安慰剂对照组上限33.7%。
- CBT组缓解率下限亦高于历史安慰剂对照组上限33.7%。
临床怎么用
- 舍曲林和CBT均可作为癫痫合并抑郁的治疗选择,舍曲林不增加癫痫发作或自杀风险。
- 应关注抑郁持续状态以评估自杀风险,改善抑郁有助于提高生活质量。
局限性
- 样本量有限,且未设安慰剂对照,历史对照比较可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Limited evidence is available to guide treatment of depression for persons with epilepsy. We evaluated the comparative effectiveness of sertraline and cognitive behavior therapy (CBT) for depression, quality of life, seizures, and adverse treatment effects. METHODS: We randomly assigned 140 adult outpatients with epilepsy and current major depressive disorder to sertraline or weekly CBT for 16 weeks. The primary outcome was remission from depression based on the Mini International Neuropsychiatric Interview (MINI). Secondary outcomes included the Quality of Life in Epilepsy Inventory-89 (QOLIE-89) seizure rates, the Adverse Events Profile (AEP), the Beck Depression Inventory, and MINI Suicide Risk Module. RESULTS: In the intention-to-treat analysis, 38 (52.8%; 95% confidence interval [CI] = ±12) of the 72 subjects assigned to sertraline and 41 (60.3%; 95% CI = ±11.6) of the 68 subjects in the CBT group achieved remission; the lower bound of efficacy for both groups was greater than our historical placebo control group upper bound of 33.7%. Difference in time to remission between groups was 2.8 days (95% CI = ±0.43; p = 0.79). The percent improvement of mean QOLIE-89 scores was significant for both the CBT (25.7%; p < 0.001) and sertraline (28.3%; p < 0.001) groups. The difference in occurrence of generalized tonic-clonic seizures between groups was 0.3% (95% CI = ±8.6; p = 0.95). Suicide risk at final assessment was associated with persistent depression (p < 0.0001) but not seizures or sertraline. INTERPRETATION: Depression remitted in just over one-half of subjects following sertraline or CBT. Despite the complex psychosocial disability associated with epilepsy, improving depression benefits quality of life. Serotonin reuptake inhibition does not appear to increase seizures or suicidality in persons with epilepsy. ANN NEUROL 2019;86:552-560.
引用
- Gilliam FG, Black KJ, Carter J, et al. A Trial of Sertraline or Cognitive Behavior Therapy for Depression in Epilepsy. Ann Neurol. 2019. PMID: 31359460. doi:10.1002/ana.25561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。